A Phase 2, Open-label, Dose-finding Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Patients With Treatment-Resistant Childhood Absence Seizures
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Cannabidiol (Primary)
- Indications Seizures
- Focus Therapeutic Use
- Sponsors INSYS Therapeutics, Inc
- 19 Dec 2017 Status changed from not yet recruiting to recruiting, according to an INSYS Therapeutics media release.
- 01 Dec 2017 Planned initiation date changed from 1 Nov 2017 to 1 Dec 2017.
- 13 Nov 2017 New trial record